Cantor Fitzgerald Analysts Lower Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND) – Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research report issued to clients and investors on Wednesday, September 4th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will post earnings of ($6.59) per share for the year, down from their previous forecast of ($4.00). Cantor Fitzgerald currently has a “Overweight” rating and a $170.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($5.60) per share.

ASND has been the topic of a number of other research reports. TD Cowen cut their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research note on Wednesday. Wells Fargo & Company cut their price objective on Ascendis Pharma A/S from $277.00 to $264.00 and set an “overweight” rating on the stock in a research report on Wednesday. Morgan Stanley upped their target price on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Oppenheimer raised Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 price target on the stock in a research report on Thursday. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.08.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $119.00 on Friday. The firm has a market capitalization of $6.93 billion, a price-to-earnings ratio of -12.38 and a beta of 0.63. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The company’s 50 day moving average price is $134.73 and its 200 day moving average price is $138.46.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in ASND. Avoro Capital Advisors LLC raised its holdings in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after acquiring an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock valued at $616,050,000 after purchasing an additional 44,580 shares in the last quarter. Capital International Investors lifted its position in shares of Ascendis Pharma A/S by 0.5% during the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after purchasing an additional 10,044 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Ascendis Pharma A/S by 5.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock worth $233,348,000 after purchasing an additional 93,185 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.